Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutic (NQ: ONTX )

0.7200 UNCHANGED
Streaming Delayed Price Updated: 3:22 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7200
Bid (Size) 0.7156 (1)
Ask (Size) 0.7700 (10)
Prev. Close 0.7200
Today's Range 0.7200 - 0.7200
52wk Range 0.6200 - 1.490
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+1.41%
+1.41%
1 Month
-7.69%
-7.69%
3 Month
-35.71%
-35.71%
6 Month
N/A
N/A
1 Year
-15.99%
-15.99%

More News

Read More
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Outlook For Onconova Therapeutics
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Edges Higher; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Gold Down Over 1%; US Composite PMI Rises In April
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.